vs
Camden Property Trust（CPT）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Camden Property Trust的1.7倍（$9.1M vs $5.3M），Camden Property Trust净利率更高（2954.1% vs -60.3%，领先3014.4%），Camden Property Trust同比增速更快（243.0% vs -49.9%），过去两年Camden Property Trust的营收复合增速更高（102.8% vs -6.7%）
Camden Property Trust是一家公开上市的房地产投资信托，专注于投资美国公寓类物业。截至2023年12月31日，公司持有美国176个公寓社区的权益，合计拥有5.98万套公寓房源，是美国排名第14位的公寓持有机构。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CPT vs PLX — 直观对比
营收规模更大
PLX
是对方的1.7倍
$5.3M
营收增速更快
CPT
高出292.9%
-49.9%
净利率更高
CPT
高出3014.4%
-60.3%
两年增速更快
CPT
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3M | $9.1M |
| 净利润 | $156.0M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | — | -51.1% |
| 净利率 | 2954.1% | -60.3% |
| 营收同比 | 243.0% | -49.9% |
| 净利润同比 | 283.5% | -184.8% |
| 每股收益（稀释后） | $1.44 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPTPLX
| Q4 25 | $5.3M | $9.1M | ||
| Q3 25 | $2.6M | $17.9M | ||
| Q2 25 | $2.6M | $15.7M | ||
| Q1 25 | $2.5M | $10.1M | ||
| Q4 24 | $1.5M | $18.2M | ||
| Q3 24 | $1.7M | $18.0M | ||
| Q2 24 | $2.6M | $13.5M | ||
| Q1 24 | $1.3M | — |
净利润CPTPLX
| Q4 25 | $156.0M | $-5.5M | ||
| Q3 25 | $108.9M | $2.4M | ||
| Q2 25 | $80.7M | $164.0K | ||
| Q1 25 | $38.8M | $-3.6M | ||
| Q4 24 | $40.7M | $6.5M | ||
| Q3 24 | $-4.2M | $3.2M | ||
| Q2 24 | $42.9M | $-2.2M | ||
| Q1 24 | $83.9M | — |
毛利率CPTPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率CPTPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
净利率CPTPLX
| Q4 25 | 2954.1% | -60.3% | ||
| Q3 25 | 4246.9% | 13.2% | ||
| Q2 25 | 3063.8% | 1.0% | ||
| Q1 25 | 1561.0% | -35.8% | ||
| Q4 24 | 2642.3% | 35.6% | ||
| Q3 24 | -246.3% | 18.0% | ||
| Q2 24 | 1646.9% | -16.4% | ||
| Q1 24 | 6533.4% | — |
每股收益（稀释后）CPTPLX
| Q4 25 | $1.44 | $-0.06 | ||
| Q3 25 | $1.00 | $0.03 | ||
| Q2 25 | $0.74 | $0.00 | ||
| Q1 25 | $0.36 | $-0.05 | ||
| Q4 24 | $0.37 | $0.10 | ||
| Q3 24 | $-0.04 | $0.03 | ||
| Q2 24 | $0.40 | $-0.03 | ||
| Q1 24 | $0.77 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.2M | $14.7M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $4.4B | $48.2M |
| 总资产 | $9.0B | $82.3M |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CPTPLX
| Q4 25 | $25.2M | $14.7M | ||
| Q3 25 | $25.9M | $13.6M | ||
| Q2 25 | $33.1M | $17.9M | ||
| Q1 25 | $26.2M | $19.5M | ||
| Q4 24 | $21.0M | $19.8M | ||
| Q3 24 | $31.2M | $27.4M | ||
| Q2 24 | $93.9M | $23.4M | ||
| Q1 24 | $92.7M | — |
总债务CPTPLX
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.7B | — | ||
| Q2 25 | $3.8B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.6B | — | ||
| Q1 24 | $3.6B | — |
股东权益CPTPLX
| Q4 25 | $4.4B | $48.2M | ||
| Q3 25 | $4.5B | $52.9M | ||
| Q2 25 | $4.6B | $49.9M | ||
| Q1 25 | $4.6B | $45.2M | ||
| Q4 24 | $4.7B | $43.2M | ||
| Q3 24 | $4.7B | $32.4M | ||
| Q2 24 | $4.9B | $28.6M | ||
| Q1 24 | $4.9B | — |
总资产CPTPLX
| Q4 25 | $9.0B | $82.3M | ||
| Q3 25 | $9.1B | $82.3M | ||
| Q2 25 | $9.1B | $78.5M | ||
| Q1 25 | $9.0B | $73.9M | ||
| Q4 24 | $8.9B | $73.4M | ||
| Q3 24 | $8.9B | $61.6M | ||
| Q2 24 | $9.1B | $91.5M | ||
| Q1 24 | $9.1B | — |
负债/权益比CPTPLX
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | 0.73× | — | ||
| Q2 24 | 0.73× | — | ||
| Q1 24 | 0.72× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $826.6M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | 5.30× | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CPTPLX
| Q4 25 | $826.6M | $2.0M | ||
| Q3 25 | $250.9M | $-3.7M | ||
| Q2 25 | $230.7M | $-5.2M | ||
| Q1 25 | $148.2M | $-5.1M | ||
| Q4 24 | $774.9M | $4.0M | ||
| Q3 24 | $261.6M | $4.1M | ||
| Q2 24 | $225.1M | $-3.6M | ||
| Q1 24 | $135.9M | — |
自由现金流CPTPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
自由现金流率CPTPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
资本支出强度CPTPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
现金转化率CPTPLX
| Q4 25 | 5.30× | — | ||
| Q3 25 | 2.30× | -1.58× | ||
| Q2 25 | 2.86× | -31.91× | ||
| Q1 25 | 3.82× | — | ||
| Q4 24 | 19.04× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 5.24× | — | ||
| Q1 24 | 1.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPT
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
